MA40106A1 - Anticorps anti-il-25 et leurs utilisations - Google Patents

Anticorps anti-il-25 et leurs utilisations

Info

Publication number
MA40106A1
MA40106A1 MA40106A MA40106A MA40106A1 MA 40106 A1 MA40106 A1 MA 40106A1 MA 40106 A MA40106 A MA 40106A MA 40106 A MA40106 A MA 40106A MA 40106 A1 MA40106 A1 MA 40106A1
Authority
MA
Morocco
Prior art keywords
antibodies
human
bind
disease
geap
Prior art date
Application number
MA40106A
Other languages
English (en)
French (fr)
Inventor
Jamie M Orengo
Jeanne Allinne
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54207847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA40106A1 publication Critical patent/MA40106A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
MA40106A 2014-09-23 2015-09-22 Anticorps anti-il-25 et leurs utilisations MA40106A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054167P 2014-09-23 2014-09-23
PCT/US2015/051407 WO2016049000A2 (en) 2014-09-23 2015-09-22 Anti-il-25 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MA40106A1 true MA40106A1 (fr) 2018-06-29

Family

ID=54207847

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40106A MA40106A1 (fr) 2014-09-23 2015-09-22 Anticorps anti-il-25 et leurs utilisations

Country Status (18)

Country Link
US (3) US9840557B2 (enExample)
EP (1) EP3197914B1 (enExample)
JP (2) JP6694877B2 (enExample)
KR (1) KR102576368B1 (enExample)
CN (1) CN107207589B (enExample)
AU (1) AU2015321517B2 (enExample)
CA (1) CA2961517C (enExample)
CL (2) CL2017000703A1 (enExample)
CO (1) CO2017003072A2 (enExample)
EA (1) EA036658B1 (enExample)
IL (1) IL251001B (enExample)
MA (1) MA40106A1 (enExample)
MX (1) MX2017003841A (enExample)
MY (1) MY185832A (enExample)
PH (1) PH12017500403A1 (enExample)
SG (2) SG10201913084PA (enExample)
WO (1) WO2016049000A2 (enExample)
ZA (1) ZA201701663B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197914B1 (en) 2014-09-23 2024-02-07 Regeneron Pharmaceuticals, Inc. Anti-il-25 antibodies and uses thereof
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CN107213463A (zh) * 2017-05-24 2017-09-29 清华大学 白介素25在银屑病的发育中的作用
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
US12258392B2 (en) 2018-11-19 2025-03-25 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-IL-25 antibodies and use thereof
JP2023508286A (ja) 2019-12-20 2023-03-02 モメンタ ファーマシューティカルズ インコーポレイテッド インテグリンアルファ１１ベータ１に対する抗体
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
TW202241928A (zh) * 2021-01-08 2022-11-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
EP4413036A4 (en) * 2021-10-05 2025-12-03 Lanier Biotherapeutics Inc MONOCLONAL ANTIBODIES DIRECTED AGAINST IL-25 AND RELATED USES
JP2025508835A (ja) * 2022-02-24 2025-04-10 シノマブ バイオサイエンス リミテッド アラーミンに対する二重特異性結合タンパク質およびその使用
WO2024206768A1 (en) * 2023-03-31 2024-10-03 Novarock Biotherapeutics, Ltd. Anti-il-25 antibodies and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) * 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
CA2795043C (en) * 2010-03-30 2019-04-23 Janssen Biotech, Inc. Humanized il-25 antibodies
WO2012097126A2 (en) * 2011-01-13 2012-07-19 The University Of Maryland, Baltimore Il-25 treatment of obesity and metabolic disorders
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
EP3197914B1 (en) 2014-09-23 2024-02-07 Regeneron Pharmaceuticals, Inc. Anti-il-25 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2017533888A (ja) 2017-11-16
PH12017500403A1 (en) 2017-07-17
ZA201701663B (en) 2023-04-26
EP3197914A2 (en) 2017-08-02
IL251001A0 (en) 2017-04-30
CA2961517C (en) 2023-05-02
SG10201913084PA (en) 2020-03-30
US11542326B2 (en) 2023-01-03
SG11201701712WA (en) 2017-04-27
AU2015321517A1 (en) 2017-04-06
KR102576368B1 (ko) 2023-09-08
CN107207589A (zh) 2017-09-26
US20180057583A1 (en) 2018-03-01
CL2017000703A1 (es) 2017-12-29
CA2961517A1 (en) 2016-03-31
JP2020075926A (ja) 2020-05-21
US20200262912A1 (en) 2020-08-20
IL251001B (en) 2021-04-29
JP6694877B2 (ja) 2020-05-20
MY185832A (en) 2021-06-11
MX2017003841A (es) 2018-02-23
KR20170063671A (ko) 2017-06-08
WO2016049000A3 (en) 2016-05-06
WO2016049000A2 (en) 2016-03-31
EA036658B1 (ru) 2020-12-04
CL2018003608A1 (es) 2019-03-15
JP6916319B2 (ja) 2021-08-11
US20160083466A1 (en) 2016-03-24
CO2017003072A2 (es) 2017-06-30
BR112017005692A2 (pt) 2017-12-12
US9840557B2 (en) 2017-12-12
EA201790441A1 (ru) 2017-08-31
EP3197914B1 (en) 2024-02-07
NZ730105A (en) 2024-01-26
US10640558B2 (en) 2020-05-05
CN107207589B (zh) 2021-04-06
AU2015321517B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
MA40106A1 (fr) Anticorps anti-il-25 et leurs utilisations
MA40035A (fr) Molécules d'anticorps de pd-l1 et leurs utilisations
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MX2023004306A (es) Un antagonista de il-4r para usarse en prevenir o tratar la alergia.
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
EA201890756A1 (ru) Антитела, которые специфически связываются с tl1a
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
CY1111577T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση ινωτικων διαταραχων
HK1250238A1 (zh) 抗angptl8抗体及其用途
WO2018069500A3 (en) Anti-lag-3 antibodies and compositions
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
EP4285923A3 (en) Antibody molecules to april and uses thereof
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
MA38478A1 (fr) Anticorps anti-pac1 humains
MA39342B2 (fr) Anticorps il -21
MX375222B (es) Compuestos y su uso para reducir los niveles de ácido úrico
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
HK1232145A1 (zh) 雙功能化合物和用於降低尿酸水平的用途
Shao et al. The scrambling index set of primitive minimally strong digraphs